Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 212

The DOI matches its Crossref record.

Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis

Miller, R. G., Moore, D. H., Gelinas, D. F., Dronsky, V., Mendoza, M., Barohn, R. J., Bryan, W., Ravits, J., Yuen, E., Neville, H., Ringel, S., Bromberg, M., Petajan, J., Amato, A. A., Jackson, C., Johnson, W., Mandler, R., Bosch, P., Smith, B., Graves, M., Ross, M., Sorenson, E. J., Kelkar, P., Parry, G., Olney, R., the WALS Study Group · 2001 · Neurology

Abstract

BACKGROUND: Preclinical and clinical studies of gabapentin in patients with ALS led the authors to undertake a phase III randomized clinical trial. METHODS: Patients were randomly assigned, in a double-blinded fashion, to receive oral gabapentin 3,600 mg or placebo daily for 9 months. The primary outcome measure was the average rate of decline in isometric arm muscle strength for those with two or more evaluations. RESULTS: Two hundred four patients enrolled, 196 had two or more evaluations, and 128 patients completed the study. The mean rate of decline of the arm muscle strength was not significantly different between the groups. Moreover, there was no beneficial effect upon the rate of decline of other secondary measures (vital capacity, survival, ALS functional rating scale, timed walking) nor was there any symptomatic benefit. In fact, analysis of the combined data from the phase II and III trials revealed a significantly more rapid decline of forced vital capacity in patients treated with gabapentin. CONCLUSION: These data provide no evidence of a beneficial effect of gabapentin on disease progression or symptoms in patients with ALS.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1212/wnl.56.7.843

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 212

Metadata

Authors
Miller, R. G., Moore, D. H., Gelinas, D. F., Dronsky, V., Mendoza, M., Barohn, R. J., Bryan, W., Ravits, J., Yuen, E., Neville, H., Ringel, S., Bromberg, M., Petajan, J., Amato, A. A., Jackson, C., Johnson, W., Mandler, R., Bosch, P., Smith, B., Graves, M., Ross, M., Sorenson, E. J., Kelkar, P., Parry, G., Olney, R., & the WALS Study Group
Venue
Neurology
Published
2001-04-10
Volume
56
Issue
7
Pages
843-848
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2001221763
Cited by
212
References
0
FWCI
8.62
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. https://app.cochat.ai/papers/10.1212/wnl.56.7.843
The paper
Miller, R. G., Moore, D. H., Gelinas, D. F., Dronsky, V., Mendoza, M., Barohn, R. J., Bryan, W., Ravits, J., Yuen, E., Neville, H., Ringel, S., Bromberg, M., Petajan, J., Amato, A. A., Jackson, C., Johnson, W., Mandler, R., Bosch, P., Smith, B., . . . the WALS Study Group. (2001). Phase III randomized trial of gabapentin in patients with amyotrophic lateral sclerosis. Neurology. https://doi.org/10.1212/wnl.56.7.843

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.